Inadequate Functioning of Nebulizer System Compressors Used by Individuals With Cystic Fibrosis

References

1. 1.↵
   1. Lopes PM

   . CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front Pharmacol 2016;7(5):1–20.

   OpenUrlCrossRef
2. 2.↵
   1. Smith S,
   2. Rowbotham NJ,
   3. Charbek E

   . Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2018;30(10):CD008319.

   OpenUrl
3. 3.↵
   1. Yang C,
   2. Montgomery M

   . Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2018;6(9):CD001127.

   OpenUrl
4. 4.↵
   1. Rubin BK

   . Air and soul: the science and application of aerosol therapy. Respir Care 2010;55(7):911–921.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Westerman EM,
   2. Boer AD,
   3. Touw DJ,
   4. Brun PPH,
   5. Le Roldaan AC,
   6. Frijlink HW,
   7. et al

   . Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. J Aerosol Med Pulm Drug Deliv 2008;21(3):269–280.

   OpenUrlPubMed
6. 6.↵
   1. Clay MM,
   2. Pavia D,
   3. Newman SP,
   4. Clarke SW

   . Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983;38(10):755–759.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Daniels T,
   2. Mills N,
   3. Whitaker P

   . Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev 2013;4(4):CD007639.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Smith EC,
   2. Denyer J,
   3. Kendrick AH

   . Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995;8(7):1214–1221.

   OpenUrlAbstract
9. 9.
   1. Geller DE

   . The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008;43(9 Suppl A):5–17.

   OpenUrl
10. 10.
    1. Berg EB,
    2. Picard RJ

    . In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care 2009;54(12):1671–1678.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Athanazio RA,
    2. Vicente L,
    3. Ferreira R,
    4. Vergara AA,
    5. Ribeiro AF,
    6. Riedi CA,
    7. et al

    . Diretrizes brasileiras de diagnóstico e tratamento da fibrose cística. J Bras Pneumol 2017;43(3):219–245.

    OpenUrl
12. 12.↵
    1. Yang C,
    2. Chilvers M,
    3. Montgomery M,
    4. Nolan SJ

    . Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2016;4(4):CD001127.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Fiel SB,
    2. Fuchs HJ,
    3. Johnson C,
    4. Gonda I,
    5. Clark AR

    . Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group. Chest J 1995;108(1):153–156.

    OpenUrl
14. 14.↵
    1. Terzano C,
    2. Petroianni A,
    3. Parola D,
    4. Ricci A

    . Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency). Eur Rev Med Pharmacol Sci 2007;11(4):225–237.

    OpenUrlPubMed
15. 15.↵
    1. Tandon R,
    2. McPeck M,
    3. Smaldone GC

    . Measuring nebulizer output: aerosol production vs gravimetric analysis. Chest 1997;111(5):1361–1365.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Ho SL,
    2. Coates AL

    . Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers. Can Respir J 1999;6(3):253–260.

    OpenUrlPubMed
17. 17.↵
    1. Loffert DT,
    2. Ikle D,
    3. Nelson HS

    . A comparison of commercial jet nebulizers. Chest 1994;106(6):1788–1793.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Standaert TA,
    2. Bohn SE,
    3. Aitken ML,
    4. Ramsey B

    . The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001;14(1):31–42.

    OpenUrlPubMed
19. 19.↵
    1. Awad S,
    2. Williams DK,
    3. Berlinski A

    . Longitudinal evaluation of compressor/nebulizer performance. Respir Care 2014;59(7):1053–1061.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Alkins SA,
    2. Hurwitz KM,
    3. Sierra A

    . Effect of driving pressure and nebulizer model on aerosol output during intermittent delivery with a dosimeter. J Aerosol Med 2002;15(1):1–6.

    OpenUrlPubMed
21. 21.↵
    1. Niven RW,
    2. Brain JD

    . Some functional aspects of air-jet nebulizers. Int J Pharm 1994;104(1):73–85.

    OpenUrl
22. 22.↵
    1. Cheng YS

    . Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech 2014;15(3):630–640.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Saiman L,
    2. Siegel JD,
    3. LiPuma JJ,
    4. Brown RF,
    5. Bryson EA,
    6. Chambers MJ,
    7. et al

    . Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35(S1):S1–S67.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Collins MS,
    2. O'Brien M,
    3. Schramm CM,
    4. Murray TS

    . Repeated hot water and steam disinfection of Pari LC Plus® nebulizers alter nebulizer output. J Cyst Fibros 2019;18(2):233–235.

    OpenUrl
25. 25.↵
    1. Reychler G,
    2. Leonard A,
    3. Van Ossel C,
    4. Godding V,
    5. Gigi J,
    6. Simon A,
    7. et al

    . Impact of hypochlorite-based disinfection on bacterial contamination of cystic fibrosis patients' home-nebulisers. J Hosp Infect 2009;72(4):351–357.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Vecellio None L,
    2. Grimbert D,
    3. Bordenave J,
    4. Benoit G,
    5. Furet Y,
    6. Fauroux B,
    7. et al

    . Residual gravimetric method to measure nebulizer output. J Aerosol Med 2004;17(1):63–71.

    OpenUrlPubMed
27. 27.↵
    1. Zhou Y,
    2. Ahuja A,
    3. Irvin CM,
    4. Kracko D,
    5. McDonald JD,
    6. Cheng YS

    . Evaluation of nebulizer performance under various humidity conditions. J Aerosol Med 2005;18(3):283–293.

    OpenUrlPubMed
28. 28.↵
    1. Rottier BL,
    2. van Erp CJP,
    3. Sluyter TS,
    4. Heijerman HGM,
    5. Frijlink HW,
    6. Boer A. D

    . Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009;22(3):263–269.

    OpenUrlCrossRefPubMed